To date, the most effective therapy for the treatment of XLH is the use of the FGF23-blocking antibody, burosumab, which prevents FGF23 phosphaturic effects and improves serum Pi levels (8–10). The gene discussed is FGF23; the disease is X-linked hypophosphatemia.